{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:50:11Z","timestamp":1776153011730,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jdermsci.2023.01.010","type":"journal-article","created":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T09:52:45Z","timestamp":1674985965000},"page":"71-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Benvitimod inhibits MCM6-meditated proliferation of keratinocytes by regulating the JAK\/STAT3 pathway"],"prefix":"10.1016","volume":"109","author":[{"given":"Zhenguo","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xunlong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdermsci.2023.01.010_bib1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1186\/s12889-019-7775-0","article-title":"The psychosocial adaptation of patients with skin disease: a scoping review","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.jdermsci.2023.01.010_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"issue":"19","key":"10.1016\/j.jdermsci.2023.01.010_bib3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jdermsci.2023.01.010_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107229","article-title":"Indirubin attenuates IL-17A-induced CCL20 expression and production in keratinocytes through repressing TAK1 signaling pathway","volume":"94","author":"Zhao","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"21","key":"10.1016\/j.jdermsci.2023.01.010_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111574","article-title":"Current concepts of psoriasis immunopathogenesis","volume":"22","author":"Vi\u010di\u0107","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jdermsci.2023.01.010_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/2589977513666210707114520","article-title":"IL-23\/Th17 axis: a potential therapeutic target of psoriasis","volume":"14","author":"Sharma","year":"2022","journal-title":"Curr. Drug Res. Rev."},{"issue":"2","key":"10.1016\/j.jdermsci.2023.01.010_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/JLB.5MR0120-439R","article-title":"Keratinocyte: a trigger or an executor of psoriasis?","volume":"108","author":"Ni","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.010_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.010_bib9","article-title":"Topical therapies for psoriasis: improving management strategies and patient adherence","volume":"35","author":"Stein Gold","year":"2016","journal-title":"Semin. Cutan Med. Surg."},{"issue":"3","key":"10.1016\/j.jdermsci.2023.01.010_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/187153012802002901","article-title":"Classical to current approach for treatment of psoriasis: a review","volume":"12","author":"Rahman","year":"2012","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"issue":"10","key":"10.1016\/j.jdermsci.2023.01.010_bib11","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/exd.14409","article-title":"The aryl hydrocarbon receptor at the forefront of host-microbe interactions in the skin: a perspective on current knowledge gaps and directions for future research and therapeutic applications","volume":"30","author":"van den Bogaard","year":"2021","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2023.01.010_bib12","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.jaad.2021.03.005","article-title":"The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinarof","volume":"85","author":"Bissonnette","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2023.01.010_bib13","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.jaad.2021.01.056","article-title":"Tapinarof and the future of topical treatments in plaque psoriasis","volume":"84","author":"Assaf","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.010_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2019.112121","article-title":"Total glucosides of paeony attenuates animal psoriasis induced inflammatory response through inhibiting STAT1 and STAT3 phosphorylation","volume":"243","author":"Li","year":"2019","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jdermsci.2023.01.010_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106659","article-title":"2'-fucosyllactose inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response via the STAT3 signaling pathway","volume":"85","author":"Lei","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.jdermsci.2023.01.010_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010171","article-title":"Psoriasis: a STAT3-centric view","volume":"19","author":"Calautti","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jdermsci.2023.01.010_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.intimp.2019.04.047","article-title":"Shikonin induces apoptosis and suppresses growth in keratinocytes via CEBP-\u03b4 upregulation","volume":"72","author":"Yu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jdermsci.2023.01.010_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107587","article-title":"miR-383 reduces keratinocyte proliferation and induces the apoptosis in psoriasis via disruption of LCN2-dependent JAK\/STAT pathway activation","volume":"96","author":"Wang","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.jdermsci.2023.01.010_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/jid.2010.255","article-title":"Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor","volume":"131","author":"Miyoshi","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.010_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cca.2021.02.005","article-title":"The DNA replication regulator MCM6: an emerging cancer biomarker and target","volume":"517","author":"Zeng","year":"2021","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"issue":"1","key":"10.1016\/j.jdermsci.2023.01.010_bib21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1186\/s12885-021-08344-z","article-title":"MCM6 indicates adverse tumor features and poor outcomes and promotes G1\/S cell cycle progression in neuroblastoma","volume":"21","author":"Gu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jdermsci.2023.01.010_bib22","doi-asserted-by":"crossref","first-page":"10829","DOI":"10.2147\/OTT.S248492","article-title":"Dihydroartemisinin inhibits the proliferation, colony formation and induces ferroptosis of lung cancer cells by inhibiting PRIM2\/SLC7A11 axis","volume":"13","author":"Yuan","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.jdermsci.2023.01.010_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117115","article-title":"The potential of Diosgenin in treating psoriasis: studies from HaCaT keratinocytes and imiquimod-induced murine model","volume":"241","author":"Wu","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.jdermsci.2023.01.010_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s10753-013-9715-y","article-title":"Targeting interleukin-22 in psoriasis","volume":"37","author":"Hao","year":"2014","journal-title":"Inflammation"},{"issue":"5","key":"10.1016\/j.jdermsci.2023.01.010_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not","volume":"87","author":"Wolk","year":"2009","journal-title":"J. Mol. Med."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.010_bib26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"11","key":"10.1016\/j.jdermsci.2023.01.010_bib27","doi-asserted-by":"crossref","first-page":"9754","DOI":"10.1074\/jbc.M212088200","article-title":"The cyclin D1-dependent kinase associates with the pre-replication complex and modulates RB.MCM7 binding","volume":"278","author":"Gladden","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"56","key":"10.1016\/j.jdermsci.2023.01.010_bib28","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1038\/onc.2008.319","article-title":"Cyclin-dependent kinase 4\/6 activity is a critical determinant of pre-replication complex assembly","volume":"27","author":"Braden","year":"2008","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jdermsci.2023.01.010_bib29","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3892\/or.2013.2585","article-title":"Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma","volume":"30","author":"Zhao","year":"2013","journal-title":"Oncol. Rep."},{"issue":"7128","key":"10.1016\/j.jdermsci.2023.01.010_bib30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.jdermsci.2023.01.010_bib31","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2023.01.010_bib32","article-title":"Diosmin restores the skin barrier by targeting the aryl hydrocarbon receptor in atopic dermatitis","volume":"81","author":"Lee","year":"2021","journal-title":"Phytomed. Int. J. Phytother. Phytopharm."},{"issue":"24","key":"10.1016\/j.jdermsci.2023.01.010_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249412","article-title":"IL-24 Negatively regulates keratinocyte differentiation induced by tapinarof, an aryl hydrocarbon receptor modulator: implication in the treatment of atopic dermatitis","volume":"21","author":"Vu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jdermsci.2023.01.010_bib34","first-page":"597","article-title":"IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation","volume":"118","author":"Ma","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jdermsci.2023.01.010_bib35","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/S0092-8674(02)00701-8","article-title":"Cytokine signaling in 2002: new surprises in the Jak\/Stat pathway","author":"O'Shea","year":"2002","journal-title":"Cell"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181123000415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181123000415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:53:09Z","timestamp":1760331189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181123000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0923181123000415"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.01.010","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benvitimod inhibits MCM6-meditated proliferation of keratinocytes by regulating the JAK\/STAT3 pathway","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}